Le Lézard
Classified in: Health, Science and technology
Subject: CCA

OpSens will Participate and Present at two Investment Conferences - Lytham Partners and Raymond James


QUEBEC CITY, June 9, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF),  a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that it will present at two investment conferences.

Lytham Partners Summer 2021 Investor Conference, June 14-16

OpSens will be participating in the Lytham Partners Summer 2021 Investor Conference on June 14-16. Louis Laflamme will be presenting on Tuesday, June 15, 2021, at 2:45 p.m. ET.

The webcast will be available on the investor page on www.OpSens.com and on https://www.webcaster4.com/Webcast/Page/2512/41473, on the day and time of the event. The presentation will be afterwards archived and available for replay.

Management will also participate in virtual one-on-one meetings throughout the event. To schedule a meeting, please contact Lytham Partners by email at [email protected]. Investors interested in attending the conference can register here.

Raymond James Human Health Innovations Conference, June 21-23 

OpSens will be participating in the Raymond James Human Health Innovations Conference on June 21-23. Louis Laflamme will be presenting on Tuesday, June 22, 2021, at 8:00 a.m. ET.

The webcast will be available on the investor page at www.OpSens.com on the day of the event and afterwards be archived and available for replay.

Management will also participate in virtual one-on-one meetings throughout the event. This conference is by invitation only. To schedule a meeting, please contact your Raymond James representative.

About OpSens Inc. (www.OpSens.com or OpSensMedical.com)

OpSens focuses mainly on products for cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

SOURCE OPSENS Inc.


These press releases may also interest you

at 08:45
HYAS Infosec, the adversary infrastructure platform provider that offers unparalleled visibility, protection, and security against all kinds of malware and attacks, today announced that it has been awarded three top recognitions from Security Today's...

at 08:44
Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features...

at 08:44
Environmental problems caused by population explosion such as global warming, natural resource depletion, deforestation, water shortage and plastic pollution are getting severe in the world. Regarding plastic pollution, micro-plastics, nano-plastics...

at 08:43
WIN (Women In Negotiation) is pleased to announce Walmart Connect as its presenting sponsor - for its eighth annual WIN Summit to be held Thursday, May 30, 2024 in New York City....

at 08:40
The "Global Cell Counting Market: Analysis By Product, By Application, By End-User, By Region Size, Trends and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global cell counting market was valued at US$9.98...

at 08:40
Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their...



News published on and distributed by: